# US 2018/0021278 A1 · Treatment or prevention of inflammation using serine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021278 A1
- Document ID: US20180021278A1
- Status: Published application
- Kind: A1
- Application number: 15/544,073
- Filed: 2016-01-22
- Published: 2018-01-25
- Earliest claimed: 2015-01-23
- Assignees: Nestec S.A.
- Applicants: Nestec S.A.
- Inventors: Magali Faure; Stephanie Blum-Sperisen; Mohamed Nabil Bosco; Viral Brahmbhatt; Denis Breuille
- Web page: https://patentgrep.com/patent/US20180021278A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods and compositions are provided that treat or prevent inflammation using serine. A therapeutically effective amount of serine is administered to an individual, for example a human or other mammal, that has inflammation or is at risk of inflammation. The methods and compositions can control and/or alleviate an inflammatory reaction of the body, such as colitis.

## Claims

### Claim 1

A method for treating inflammation comprising administering to an individual having inflammation a composition comprising a therapeutically effective amount of serine.

### Claim 2 (depends on 1)

The method of claim 1 wherein the composition is administered by a route selected from the group consisting of oral, topical, enteral and parenteral.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is in a form selected from the group consisting of a nutritionally complete product, a drink, a dietary supplement, a meal replacement, a food additive, a supplement to a food product a powder for dissolution, an enteral nutrition product, an infant formula, and combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inflammation is selected from the group consisting of acute inflammation, skin inflammation, inflammatory bowel disease including crohn's disease and/or ulcerative colitis, inflammatory bowel syndrome, liver inflammation, allergy, atopy, bone inflammation, rheumatoid arthritis, systemic lupus, Gougerot-Sjogren's syndrome, Reiter's syndrome, poliomyelitis, dermato-myositis, thyroiditis, Basedow, Hashimoto, type I diabetes, Addison's disease, auto-immunes hepatitis, celiac disease, Biermer's disease, multiple sclerosis, myasthenia, encephalomyelitis, eye inflammation, obesity-associated inflammation, age-related low-grade inflammation, Blau's syndrome, Alzheimer's disease, cardiovascular diseases, atherosclerosis, metabolic syndrome, gingivitis, paronditis, and combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the individual is selected from the group consisting of an infant, a child, an adolescent, an adult and an elderly person.

### Claim 6 (depends on 1)

The method of claim 1, wherein the nutritional composition further comprises at least one component selected from the group consisting of a prebiotic, a probiotic, a synbiotic, an additional amino acid, a protein, a nucleotide, a fish oil, a non-marine source of omega-3 fatty acids, a phytonutrient, an antioxidant, and combinations thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is administered in an amount to provide about 0.07 to about 0.35 g of serine/kg of body weight of the individual per day.

### Claim 8

A method for preventing inflammation comprising administering to an individual at risk thereof a composition comprising a therapeutically effective amount of serine.

### Claim 9 (depends on 8)

The method of claim 8 wherein the composition is administered by a route selected from the group consisting of oral, topical, enteral and parenteral.

### Claim 10 (depends on 8)

The method of claim 8, wherein the composition is in a form selected from the group consisting of a nutritionally complete product, a drink, a dietary supplement, a meal replacement, a food additive, a supplement to a food product a powder for dissolution, an enteral nutrition product, an infant formula, and combinations thereof.

### Claim 11 (depends on 8)

The method of claim 8, wherein the inflammation is selected from the group consisting of acute inflammation, skin inflammation, inflammatory bowel disease including crohn's disease and/or ulcerative colitis, inflammatory bowel syndrome, liver inflammation, allergy, atopy, bone inflammation, rheumatoid arthritis, systemic lupus, Gougerot-Sjogren's syndrome, Reiter's syndrome, poliomyelitis, dermato-myositis, thyroiditis, Basedow, Hashimoto, type I diabetes, Addison's disease, auto-immunes hepatitis, celiac disease, Biermer's disease, multiple sclerosis, myasthenia, encephalomyelitis, eye inflammation, obesity-associated inflammation, age-related low-grade inflammation, Blau's syndrome, Alzheimer's disease, cardiovascular diseases, atherosclerosis, metabolic syndrome, gingivitis, paronditis, and combinations thereof.

### Claim 12 (depends on 8)

The method of claim 8, wherein the individual is selected from the group consisting of an infant, a child, an adolescent, an adult and an elderly person.

### Claim 13 (depends on 8)

The method of claim 8, wherein the nutritional composition further comprises at least one component selected from the group consisting of a prebiotic, a probiotic, a synbiotic, an additional amino acid, a protein, a nucleotide, a fish oil, a non-marine source of omega-3 fatty acids, a phytonutrient, an antioxidant, and combinations thereof.

### Claim 14 (depends on 8)

The method of claim 8, wherein the composition is administered in an amount to provide about 0.07 to about 0.35 g of serine/kg of body weight of the individual per day.

### Claim 15

(canceled)

### Claim 16

A method for treating or preventing IBD, comprising administering to an individual in need thereof or at risk thereof a composition comprising a therapeutically effective amount of serine.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

A method according to claim 16, wherein the IBD is Crohn's disease.

### Claim 19 (depends on 16)

A method according to claim 16, wherein the IBD is Ulcerative colitis.

### Claim at position 20

20-22. (canceled)
